It is beginning to be recogrized that the goal of antihypertensive therapy is not mereiy to reduce blood pressure, but also to ptevent -and even reverse -the damage to vessels and to organs'-' associated with hypertension. Only in this way can one brealc out of the 'vicious circle' of hypertension and vascular and organ damage and overcome the widespread morbidity and mortality in hypertension-related heart disease, cerebrovascular accidents and renal fail&.
At a recent series of workshops*, the ceuses and consequences of end-organ and vessel wall damage, as weIl as the role of angiotensin I converting enzyme (ACE) inhibitors, such as cilaxap&', were discussed.
Hypertension and vessel wall damage
A. Doyle (University of Melbourne) pointed out that hypertension is associated with proliferation and remodelling of the vascular smoot!? muscle cells. These changes are aggravated by atherosclerosis, leading to clinical consequences dependent on the end-organ affected: coronary atherosclerosis, angina, myocardial infarction and heart failure, renal insufficiency, and cerebrovascular accidents. The precise signal for the vascular changes is not well understood, but physical factors, mainly the increase in blood flow rather than of the pressure per se, seem to play an important role (M. Mulvany, University of Aarhus). Moreover, it is becoming clear that the vascular hypertrophy and tissue damage are related to the induction of a number of growth factors (platelet-derived, epidermal and fibroblast growth factor&"), proto-oncogenes, and hormones Recent work has focused on the endothelium, which produces several vasoactive substances, in particular endothelium-derived relaxing factor. The inhibitory effects of the endothelium against vasoconstrictor stimuli decrease with age and hypertension (T. Liischer, University
Hospital, Basel).
Although it is relatively easy to determine the extent of vascular damage due to hypertension in experimental animals, this is much more ditficult in patients. However, the relationship between blood pressure and arterial diameter or compliance can be used as an index of arterial stiffness and structural changes in humans (A. Simon, Broussais Hospital, Paris). Moreover, W. Birkenhhger (Erasmus University, Rotterdam) described several other parameters that can be used in situations such as clinical trials, where the available technological potentials have to be weighed against factors such as convenience, compliance of trial subjects, and cost.
Hypertension and the heart
The changes that hypertension induces in the structure and hmction of the heart and its associated vasculahire are clearly of great clinical significance, but which changes can best be used to predict outcome and to direct therapy? In uncomplicated essential hypertensive patients, left ventricular hypertrophy emerged as a significant risk factor for future morbid events -independent of age, blood pressure or cardiac output (R. Fagard, University of Leuven). Although the left ventricular systolic function may be normal in hypertension, the diastolic function is frequently 239 impaired (J. Rosenthal, University Medical Centre, Ulm). Another major risk factor in hypertension, particularly of the renovascular type. is the slowness of the response of the coronary blood flow to increasing myocardial demand. This 'inappropriate' blood flow appears to bt?:zzz to elevated angiotensin II levels (F. Magrini, University of Milan).
Hypertension and the kidney
Renal disease is both the cause and consequence of hypertension and the total avai!able g!omerular filtration area is the prime factor involved in the 'vicious spiral' of increasing high blood pressure and diminishing renal function. Therefore, the higher the microalbuminurea, the higher the incidence of hypertension (B. M. Brenner, Harvard Medical School). While no therapy is available for directly increasing the number of glomeruli or the growth of glomerular capillaries, interventions that control systemic and glomerular capillary hypertension could interrupt this cycle.
Angiokrrsin and the brain
Although the existence of a renin-angiotensin system has been established in several tissues, an appreciation of its importance, particularly in the brain, is only now emerging. Ligand-binding studies in the rat brain have identified two types of angiotensin receptor (see also Ref. 7): one located in the periventricular areas (AT, receptor) and the other in the midbrain, brain stem and cerebellum (AT2 receptor). The majority of the pharmacological actions of angiotensin in the periphery and, probably, in the brain are mediated by AT, receptors, while the function of AT, receptors is not known (T. Unger. University of Heidelberg). 8. llunnemann (Karolinska Institute) reported that angiotensin fragments are released from nerve endings to activate postsynaptic receptors ('hard-wired transmission), but they may also diffuse to adjacent areas or be released from glial cells to act on olher specific receptors ('volume' transmission) . Among the several cmtral effects of angiotensin 11, the increase in sympathetic activity is well recognized (P. R. Saxena, Erasmus University, Rotterdam), but the peptide may also disrupt cognitive functions (T. J. Williams, University of Bradford).
ACE inhibition and vessel and oa;md=%e
Beveral speakers addressed the question: does treatment with antihypertensive drugs, especially ACE inhibitors, reverse vessel and oqan damage in addition to lowering blood pressure? Reviewing the limtted data available on this subject, Doyle pointed out that methyldopa and, particularly, ACE inhibitors can generally reverse or prevent the cardiac hypertrophy, vascular proliferation and renal damage associated with experimental and clinical hypertension, but antihypertensive drugs such as hydralazine, prazosin and B-admnoceptor antagonists usually fail to do so. Simon reported that in hypertensive subjects no active or passive changes in arterial compliance are observed after treatment with ketanserin or urapidil, but the Ca*+ channel blockers nitrendipine and nicardipine acttvely increase compliance as well as larue arterv diameter. W. H. Van , TiPS-July 1991 F'nl. 121 Gilst (University of Groningen) reported that ACE inhibitors increase coronary blood flow in the rat isolated heart; it is, however, unclear whether these effects are due to a decrease in angiotensin II or to an increase in bradykinin concentration in the heart. ln humans, although the effects of ACE inhibitors on coronary blood flow per se may not be consistent, these drugs do antagonize exercise-induced coronary vasoconstriction (Magrini).
In patients with renovascular hypertension, particularly those with bilateral stenosis or stenosis of a solitary kidney, the use of ACE inhibitors may be associated with a reversible deterioration of renal function (A. Mimran, Lepeyronie Hospital, MontPelier). However, these drugs cause fewer metabolic side-e&c& in patients with diabekic nephmpathy (M. Beaufils, Tenon Hospital, Paris) and they lower urinary protein leakage by decmasing intraglomerular pressure, both in diabetic and non-diabetic renal disease (P. E. de Jong, Academic Medical Hospital, GroY#enand H. H. Parving, Hvideue ospital, Rkqenbo%, C%enhsgcn). In the Cl%, Williams reported that ACE inhibitors can improve both basal and impaired (e.g. by scopolamine or nucleus basalis lesion) cognitive function in rodents; this improvement seems to be related in part to acetylcholine release in the brain. In humans, the data tqgest that impairment, whereas @adreno-ceptor anbqonists are only weakly impEcated and ACE inhibitors are least likely to affect cognitive function (C. J. Bulpitt, Royal Postgraduate Medical school, London). Preclinical data on the new ACE inhibitor cilazapril, which has a potent antihypertensive effect in both experimental animals and humans, demonstrated that chronic administration to spontaneously hyperknsive rats decreases cardiac mass, increases coronary and cerebral vascular reserve, and prevents and mverses media hypertrophy in, for example, the coronary, mesenteric, renal and carotid vascular beds (J-P._Clozel, Hoffmann& Roche; see Fig. 1 (k&Reviewartldepp.~272).
In higher organisms, the glycosaminc$ycans~are part of larger utr\l+n9lvcan molecules3. Thev are tocate$ 'mainly in extraceriular matrices and at cell surfaces, and interact strongly with a broad range of proteins (e.g. growth factors, lipoproteins, complement components, cell-attachment glycopmteins and pmtease inhibitors)". These high molecular mass (50-100 bDa) polyanionic polysac&arldes are divided into different classes according to their carbohydrate composition (heparin, heparan sulphate, dermatan sulphate, chondmitin sulphate, hyahuonic acid and keratan sulphate). Within each class, further structural diversity can occur through variation of specific carbohydate residues and by varying the position of N-acetyl and N,O-sulphate gmups3"b. The polysaccharide chain of glycosaminoglycans consists of long stretches of structurally welldefined alternating sequences, together with small he@mgeneous domain&'. These domains are most likely to confer functional specific@ for protein interactions.
For example, in the heparinantithmmbin III interaction, binding of heparin induces a conformational change in antithmmbin III, thereby accelerating the inactivation of blood coagulation factors (e.g. factor IIa and factor Xa) mediated by antithmmbin III. Approximately 80% of the heparin molecule consists of a repeating disaccharide unit (cu+idoWranosyluronic acid-l-sulphate and 2-deoxy-2-sulphaminoa-o-glucopyranose-6-sulphate, each of which is glycosidically linked through position 4; Ref. 6), while the rest of the molecule is heterogeneous and incorporates other types of saccharides such as D-glucumnic acid.
The findine that a hetemgeneous pentasaccharide region of heparin activates the pmtease inhibitor antithmmbin III challenged the widespread assumption that the bioactivity of heparin (and probably of other glycosaminoglycans) might be due to its polyanionic character. The specificity of the interaction of the sulphated pentasaccharide with the protein (see Fig. 1 ) became apparent when heparin pentasaccharide analogues were synthesized and tested for inhibition of blood coagulation factor Xa'@13.
The presence and spatial orientation14J5 of particular sulphate and carboxylate groups (highlighted in red in Fig. 1 ) were shown to be essential for biological activity. Moreover, essential sulphate groups cannot be replaced by phosphate groups16. Analogues in which only one chiral centre has been inverted (indicated by # in Fig. 1 ) were found to be inactive (M. Petitou and C. A. A. van Boeckel, unpublished) , while the presence of a rigid carbohydrate moiety (i.e. the glucumnic acid unit) may be as important as the presence of the essential charged gmups'7. Furthermor:, analogues with extra sulphate groups may become less active (particularly unfavourable is a sulphate group at the 3-O position of the glucumnic acid unit, C. A. A. van Boeckel, unpublished), while additional sulphation at one particular position, the 3-O at the reducing end unit (indicated by an asterisk in Fig. l) , provides the most potent malogue found so far, 0RC31550'6~'9.
The heuristics described above indicate that for a good interaction with antithmmbin III the pmtasaccharide must adhere to very stringent criteria imposed by the three-dimensional structure of the protein. However, no crystallographic studies have yet been reported from which such specific pmtein-gIycosaminoglycan interactions can be visualized. Indeed, there is a paucity of three-dimensional information on carbohydrate-protein interactions in general, and studies to date have
